While the presence of ICOS+ TA-Tregs in TILs were correlated with a poor prognosis in human tumors, effector CD4+ICOS+ T cells were found to be enriched in the peripheral blood and tumor tissues of patients treated with anti-CTLA-4 antagonistic mAbs. This evidence concerns the gene ICOS and neoplasm.